Pharmacological analysis of the inhibitor of EGF/EGFR, piperlongumine, had been shown to have an anti-tumor effect on HCC, which was achieved through inhibiting angiogenesis via the EGF/EGFR signaling pathway. Here, EGF is linked to hepatocellular carcinoma.